Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (692)	10/23/2002 11:10:34 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 3561

Not that it is immediate threat, Celltech is working on CDP484, an anti-IL-1B receptor antagonist which is a peg-Fab with a 14 day half-life expressed in microbial system. Expected in clinic '03. (I suppose, by being different MOA, it is not really direct competitor.) For each of its peg-Fabs, all of which will be the third or so biologic in crowded fields, Celltech clearly views its expression technology as a strategic weapon. It will be interesting to see, years from now, how much appetite it has to compete on price.